Dr. Reddy's and CHD Bioscience in pact for drug to mitigate surgical site infections

摘要

Dr. Reddy's Laboratories Ltd. and CHD Bioscience Inc., a privately-held biopharmaceutical company, have announced a global licensing agreement for the clinical development and commercialisation of Dr. Reddy's phase III clinical trial candidate, DFA-02. It is intended to be used for the prevention of surgical site infections, following non-emergency, elective colorectal surgery. Phase II studies for DFA-02 have been successfully completed, and the product will be transitioning to pivotal Phase III registration studies.